ARGUMENTS AND REMARKS






Remarks







Claims 1-7 are amended and are supported by the claims as originally filed and by the specification, especially by **Examples**. No new matter is added. Applicants respectfully request entry of this amendment.



Inventive Step

Specifically, the Examiner states that the application of claims 1-7 cannot be considered inventive. The applicant has different opinions.

Claims 1-7 are amended and are supported by the claims as originally filed and by the specification, especially by **Examples of Compounds** as follow:


No.	Structural Formula	Chemical Name
1		(4*R*,5*S*,6*S*)-6-[(*R*)-1-hydroxyethyl]-4-methyl-3-[(7*S*,8a*S*)-2-methyloctahydropyrrolo[1,2-*a*]pyrazin-7-ylthio]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
2		(4*R*,5*S*,6*S*)-6-[(*R*)-1-hydroxyethyl]-3-[(7*S*,8a*S*)-2-Isopropyl-octahydropyrrolo[1,2-*a*]pyrazin-7-ylthio]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
3		(4*R*,5*S*,6*S*)-3-[(7*S*,8a*S*)-2-benzyloctahydropyrrolo[1,2-*a*]-pyrazin-7-ylthio]-6-[(*R*)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
4		(4*R*,5*S*,6*S*)-3-[(7*S*,8a*S*)-2-acetyloctahydropyrrolo[1,2-*a*] pyrazin-7-ylthio]-6-[(*R*)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
5		(4*R*,5*S*,6*S*)-6-[(*R*)-1-hydroxyethyl]-3-[(7*S*,8a*S*)-2-isobutyryl-octahydropyrrolo[1,2-*a*]pyrazin-7-ylthio]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

6		(4*R*,5*S*,6*S*)-3-[(7*S*,8a*S*)-2-benzoyloctahydropyrrolo[1,2-*a*]-pyrazin-7-ylthio]-6-[(*R*)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
7		(4*R*,5*S*,6*S*)-6-[(*R*)-1-hydroxyethyl]-4-methyl-7-oxo-3-[(7*S*,8a*S*)-2-picolinoyloctahydropyrrolo[1,2-*a*]pyrazin-7-ylthio]-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
8		(4*R*,5*S*,6*S*)-6-[(*R*)-1-hydroxyethyl]-4-methyl-7-oxo-3-[(7*S*,8a*S*)-2-(4-sulfamoylbenzoyl)octahydropyrrolo[1,2-*a*]pyrazin-7-ylthio]-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
9		(4*R*,5*S*,6*S*)-6-[(*R*)-1-hydroxyethyl]-4-methyl-7-oxo-3-[(7*S*,8a*S*)-2-sulfamoyloctahydropyrrolo[1,2-*a*]pyrazin-7-ylthio]-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
12		(4*R*,5*S*,6*S*)-3-((7*S*,8a*S*)-2-(2-(dimethylamino)acetyl)octahydro-pyrrolo[1,2-*a*]pyrazin-7-ylthio)-6-((*R*)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
13		(4*R*,5*S*,6*S*)-3-((7*S*,8a*S*)-2-(2-(dimethylamino)propionyl)octa-hydropyrrolo[1,2-*a*]pyrazin-7-ylthio)-6-((*R*)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

14		(4*R*,5*S*,6*S*)-6-[(*R*)-1-hydroxyethyl]-4-methyl-3-[(7*S*,8a*S*)-2-(2-morpholinoacetyl)octahydropyrrolo[1,2-*a*]pyrazin-7-ylthio]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
16		(4*R*,5*S*,6*S*)-6-[(*R*)-1-hydroxyethyl]-3-[(7*S*,8a*S*)-2-(2-hydroxy-ethyl)octahydropyrrolo[1,2-*a*]pyrazin-7-ylthio]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

So, the claim can be displayed as follow:

A compound of formula (I), or its pharmaceutically acceptable salts:



(I)

Wherein

R^1 is C_{1-4} alkyl;

R^2 is

(1) C_{1-4} alkyl, which is optionally substituted by one X^1,

X^1 is independently selected fromhydroxyl, phenyl,

(2) -CO-Y,

Y is C_{1-4} alkyl which is optionally substituted by one Y^1, or phenyl, pyridyl, which is optionally substituted by one Y^2,

Y^1 represents independently selected from bis-(C_{1-4} alkyl)amine, C_{3-6} cycloalkyl,

Y^2 represents independently selected from amino sulfonyl, amino sulfonyl C_{1-4} alkyl,

(3) $-S(O)_m-Z$, m is 1 or 2,

Z is amino;


R^3 is hydrogen.

All in all, the subject matter of claims 1-7 (amendment) of our application can be considered inventive.

AMENDMENTS OF THE CLAIMS

CLAIMS

1. A compound of formula (I), or its pharmaceutically acceptable salts~~, or its readily hydrolyzed ester, or its solvate, or its stereoisomer~~:



(I)

Wherein

R^1 is C_{1-4} alkyl;

R^2 is

(1) C_{1-4} alkyl, which is optionally substituted by one~~-to-three~~ X^1,

X^1 is independently selected from~~carboxyl,~~ hydroxyl, ~~amino, C_{1-4}-alkoxy, halogenated C_{1-4}-alkoxy, C_{1-4}-alkyl-amino, bis-(C_{1-4}-alkyl)amine, C_{1-4}-alkyl-carbonyl, carbamoyl, amino-sulfonyl, guanidino, C_{3-6}-cycloalkyl,~~ phenyl, ~~5-6-membered heteroaryl or 3-7 membered heterocyclic,~~

~~C_{3-6}-cycloalkyl, phenyl, 5-6-membered heteroaryl or 3-7-membered heterocyclic of the said X^1 can be further substituted by the following substituents: halogen, C_{1-4}-alkyl, halogenated C_{1-4}-alkyl, C_{1-4}-alkoxy, halogenated C_{1-4}-alkoxy, C_{1-4}-alkyl-amino, bis-(C_{1-4}-alkyl)-amino, C_{1-4}-alkyl-carbonyl, carbamoyl, carbamoyl-C_{1-4}-alkyl, amino-sulfonyl, amino-sulfonyl-C_{1-4}-alkyl, or guanidino,~~

~~(2) C_{3-6}-cycloalkyl, phenyl, 5-6-membered heteroaryl or 3-7-membered heterocyclic which is optionally substituted by one to three X^2,~~

~~X^2 is independently selected from halogen, amino, C_{1-4}-alkyl, halogenated C_{1-4}-alkyl, C_{1-4}-alkoxy, halogenated C_{1-4}-alkoxy, C_{1-4}-alkyl-amino, bis-(C_{1-4}-alkyl)-amino, bis-(C_{1-4}-alkyl)-amino-C_{1-6}-alkyl, C_{1-4}-alkyl-carbonyl, carbamoyl, carbamoyl-C_{1-4}-alkyl, amino-sulfonyl, amino-sulfonyl-C_{1-4}-alkyl, or guanidino.~~

(~~3~~2) -CO-Y,

Y is C_{1-4} alkyl which is optionally substituted by one~~-to-three~~ Y^1, or ~~C_{3-6}-cycloalkyl,~~ phenyl, pyridyl ~~5-6-membered heteroaryl or 3-7-membered heterocyclic~~ which is optionally substituted by one ~~to-three~~ Y^2,

Y^1 represents ~~the above-defined X^1~~ independently selected from bis-(C_{1-4} alkyl)amine,

C_{3-6} cycloalkyl,

and Y^2 represents the above defined X^2, independently selected from amino sulfonyl, amino sulfonyl C_{1-4} alkyl,

(43) $-S(O)_m-Z$, m is 1 or 2,

Z is amino; C_{1-4} alkyl amino, bis-(C_{1-4} alkyl)amino, or C_{1-4} alkyl which is optionally substituted by one to three Y^1, or C_{3-6} cycloalkyl, phenyl, 5-6 membered heteroaryl or 3-7 membered heterocyclic which is optionally substituted by one to three Y^2;

Y^1 represents the above defined X^1 and Y^2 represents the above defined X^2; and

R^3 is hydrogen.

2. A compound claimed in claim 1, or its pharmaceutically acceptable salts, or its readily hydrolyzed ester, or its solvate, or its stereoisomer:

Wherein

R^1 is methyl;

R^2 is

(1) C_{1-4} alkyl, which is optionally substituted by one to three X^1,

X^1 is independently selected from carboxyl, hydroxyl, amino, C_{1-4} alkoxy, halogenated C_{1-4} alkoxy, C_{1-4} alkyl amino, bis-(C_{1-4} alkyl)amino, carbamoyl, amino sulfonyl, phenyl, pyridyl, piperidinyl, piperazinyl or morpholinyl,

The phenyl, pyridyl, piperidinyl, piperazinyl or morpholinyl of the said X^1 can be further substituted by the following substituents: halogen, C_{1-4} alkyl, halogenated C_{1-4} alkyl, C_{1-4} alkoxy, halogenated C_{1-4} alkoxy, C_{1-4} alkyl amino, bis-(C_{1-4} alkyl) amino, C_{1-4} alkyl carbonyl, carbamoyl, carbamoyl C_{1-4} alkyl, or amino sulfonyl,

(2) phenyl, pyridyl, piperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl, thiazole, 4,5-dihydro-thiazolyl, or cyclopropyl group which is optionally substituted by one to three X^2,

X^2 is independently selected from halogen, C_{1-4} alkyl, C_{1-4} alkyl amino, bis-(C_{1-4} alkyl) amino, carbamoyl, carbamoyl C_{1-4} alkyl, amino sulfonyl,

(32) $-CO-Y$,

Y is C_{1-4} alkyl which is optionally substituted by one to three Y^1, or phenyl, pyridyl, piperidinyl, piperazinyl, morpholinyl, pyrrolidinyl, furanyl, thiazolyl or 4,5-dihydro-thiazolyl which is optionally substituted by one to three Y^2,

Y^1 is independently selected from amino, C_{1-4} alkyl amino, bis-(C_{1-4} alkyl) amino, carbamoyl, guanidino, phenyl, pyridyl, piperidinyl, morpholinyl or pyrrolidinyl,

Y^2 is independently selected from ~~halogen, amino, C_{1-4}-alkyl, C_{1-4}-alkyl-amino, bis-(C_{1-4}-alkyl) amino, carbamoyl, carbamoyl-C_{1-4}-alkyl or~~ amino sulfonyl,

(43) -$S(O)_m$-Z, m is 1 or 2,

Z is amino~~;~~

~~-C_{1-4}-alkyl-amino, bis-(C_{1-4}alkyl)amino, or C_{1-4}-alkyl which is optionally substituted by one to three Y^1, or phenyl, pyridyl, piperidinyl, piperazinyl, morpholinyl or pyrrolidinyl which is optionally substituted by one to three Y^2,~~

~~Y^1 and Y^2 represents the above defined;~~ and

R^3 is hydrogen.

3. A compound claimed in claim 2, or its pharmaceutically acceptable salts, ~~or its readily hydrolyzed ester, or its solvate, or its stereoisomer~~:

Wherein

R^1 is methyl;

R^2 is

(1) methyl, ethyl, isopropyl, which is optionally substituted by one to three X^1,

X^1 is independently selected from hydroxyl~~, dimethylamine,~~ or phenyl ~~or pyridyl, The phenyl or pyridyl of the said X^1 can be further substituted by the following substituents: halogen, methyl, carbamoyl, carbamoyl-methyl, or amino-sulfonyl.~~

~~(2) phenyl, pyridyl, tetrahydrofuranyl, thiazole, 4,5-dihydro-thiazolyl, or cyclopropyl group which is optionally substituted by one to three X^2,~~

~~X^2 is independently selected from halogen, methyl, carbamoyl, amino-sulfonyl,~~

(~~3~~2) -CO-Y,

Y is methyl, ethyl or isopropyl which is optionally substituted by one ~~to three~~ Y^1, or phenyl, pyridyl~~, piperidinyl, piperazinyl, pyrrolidinyl~~ which is optionally substituted by one ~~to three~~ Y^2,

Y^1 is independently selected from dimethylamine or ~~, carbamoyl, guanidino, phenyl, pyridyl, piperidinyl,~~ morpholinyl ~~or pyrrolidinyl~~,

Y^2 is independently selected from ~~halogen, methyl, carbamoyl, carbamoyl-methyl-or~~ amino sulfonyl,

(43) -$S(O)_m$-Z, m is 1 or 2,

Z is amino~~, dimethylamino, dimethylamino-methyl, methylpiperazine-or-morpholine methyl~~; and

R^3 is hydrogen.

4. A compound claimed in claim 3, or its pharmaceutically acceptable salts~~, or its readily hydrolyzed ester, or its solvate, or its stereoisomer~~:

Wherein

R^1 is methyl;

R^2 is

(1) methyl, ethyl, or isopropyl, which is optionally substituted by one to two X^1,

X^1 is independently selected from phenyl,

~~The said phenyl of X^1 can be further substituted by halogen, methyl, carbamoyl, or amino sulfonyl.~~

(2) -CO-Y,

Y is methyl, ethyl or isopropyl, which is optionally substituted by one ~~to two~~ Y^1, or phenyl, pyridyl, ~~piperidinyl,~~ which is optionally substituted by one ~~to two~~ Y^2,

Y^1 is independently selected from dimethylamine~~, guanidino, phenyl, pyridyl,~~ or morpholinyl,

Y^2 is independently selected from ~~halogen, methyl, carbamoyl, or~~ amino sulfonyl,

(3) $-S(O)_m$-Z, m is 1 or 2,

Z is amino~~, or dimethylamino~~; and

R^3 is hydrogen.

5. A compound claimed in claim 4, or its pharmaceutically acceptable salts, ~~or its readily hydrolyzed ester, or its solvate, or its stereoisomer,~~ and the said compound is selected from the followings:

(4*R*,5*S*,6*S*)-3-[(7*S*,8a*S*)-2-benzyloctahydropyrrolo[1,2-*a*]-pyrazin-7-ylthio]-6-[(*R*)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid,

(4*R*,5*S*,6*S*)-3-[(7*S*,8a*S*)-2-acetyloctahydropyrrolo[1,2-*a*]pyrazin-7-ylthio]-6-[(*R*)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid,

(4*R*,5*S*,6*S*)-6-[(*R*)-1-hydroxyethyl]-3-[(7*S*,8a*S*)-2-isobutyryl-octahydropyrrolo[1,2-*a*]pyrazin-7-ylthio]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid,

(4*R*,5*S*,6*S*)-3-[(7*S*,8a*S*)-2-benzoyloctahydropyrrolo[1,2-*a*]-pyrazin-7-ylthio]-6-[(*R*)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid,

(4*R*,5*S*,6*S*)-6-[(*R*)-1-hydroxyethyl]-4-methyl-7-oxo-3-[(7*S*,8a*S*)-2-picolinoyloctahydropyrrolo[1,2-*a*]pyrazin-7-ylthio]-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid,

(4*R*,5*S*,6*S*)-6-[(*R*)-1-hydroxyethyl]-4-methyl-7-oxo-3-[(7*S*,8a*S*)-2-(4-sulfamoylbenzoyl)octahydropyrrolo[1,2-*a*]pyrazin-7-ylthio]-1-azabicyclo[3.2.0]hept-2-ene-2-carboxyli

c acid,

(4*R*,5*S*,6*S*)-6-[(*R*)-1-hydroxyethyl]-4-methyl-7-oxo-3-[(7*S*,8a*S*)-2-sulfamoyloctahydropyrrolo[1,2-*a*]pyrazin-7-ylthio]-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid,

(4*R*,5*S*,6*S*)-6-[(*R*)-1-hydroxyethyl]-4-methyl-7-oxo-3-[(7*S*,8a*S*)-2-(4-sulfamoylbenzyl)octahydropyrrolo[1,2-*a*]pyrazin-7-ylthio]-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid,

(4*R*,5*S*,6*S*)-3-[(7*S*,8a*S*)-2-(2-guanidinoacetyl)octahydropyrrolo[1,2-*a*]pyrazin-7-ylthio]-6-[(*R*)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid,

(4*R*,5*S*,6*S*)-3-((7*S*,8a*S*)-2-(2-(dimethylamino)acetyl)octahydro-pyrrolo[1,2-*a*]pyrazin-7-ylthio)-6-((*R*)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid,

(4*R*,5*S*,6*S*)-3-((7*S*,8a*S*)-2-(2-(dimethylamino)propionyl)octa-hydropyrrolo[1,2-*a*]pyrazin-7-ylthio)-6-((*R*)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid,

(4*R*,5*S*,6*S*)-6-[(*R*)-1-hydroxyethyl]-4-methyl-3-[(7*S*,8a*S*)-2-(2-morpholinoacetyl)octahydropyrrolo[1,2-*a*]pyrazin-7-ylthio]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid,

~~(4*R*,5*S*,6*S*)-6-[(*R*)-1-hydroxyethyl]-4-methyl-3-[(7*S*,8a*S*)-2-(1-methylpiperidine-4-carbonyl)octahydropyrrolo[1,2-*a*]pyrazin-7-ylthio]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid,~~ and

(4*R*,5*S*,6*S*)-6-[(*R*)-1-hydroxyethyl]-3-[(7*S*,8a*S*)-2-(2-hydroxy-ethyl)octahydropyrrolo[1,2-*a*]pyrazin-7-ylthio]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid.


6. A pharmaceutical dosage form comprising a compound claimed in claims 1-5, or its pharmaceutically acceptable salts, ~~or its readily hydrolyzed ester, or its solvate, or its stereoisomer,~~ characterized in that the said dosage form contains one or more pharmaceutical carriers.

7. The use in the manufacture of a medicament for the treatment and/or prevention of infectious diseases comprising a compound claimed in claims 1-5, or its pharmaceutically acceptable salts, ~~or its readily hydrolyzed ester, or its solvate, or its stereoisomer~~.

AMENDMENTS OF THE CLAIMS (Clear)

CLAIMS

1. A compound of formula (I), or its pharmaceutically acceptable salts:



(I)

Wherein

R^1 is C_{1-4} alkyl;

R^2 is

(1) C_{1-4} alkyl, which is optionally substituted by one X^1,

X^1 is independently selected fromhydroxyl, phenyl,

(2) -CO-Y,

Y is C_{1-4} alkyl which is optionally substituted by one Y^1, or phenyl, pyridyl, which is optionally substituted by one Y^2,

Y^1 represents independently selected from bis-(C_{1-4} alkyl)amine, C_{3-6} cycloalkyl,

Y^2 represents independently selected from amino sulfonyl, amino sulfonyl C_{1-4} alkyl,

(3) -$S(O)_m$-Z, m is 1 or 2,

Z is amino;

R^3 is hydrogen.

2. A compound claimed in claim 1, or its pharmaceutically acceptable salts:

Wherein

R^1 is methyl;

R^2 is

(1) C_{1-4} alkyl, which is optionally substituted by one X^1,

X^1 is independently selected from hydroxyl, phenyl,

(2) -CO-Y,

Y is C_{1-4} alkyl which is optionally substituted by one Y^1, or phenyl, pyridyl, which is optionally substituted by one to three Y^2,

Y^1 is independently selected from bis-(C_{1-4} alkyl) amino, morpholinyl

Y^2 is independently selected from amino sulfonyl,

(3) -$S(O)_m$-Z, m is 1 or 2,

Z is amino; and

R^3 is hydrogen.

3. A compound claimed in claim 2, or its pharmaceutically acceptable salts:

Wherein

R^1 is methyl;

R^2 is

(1) methyl, ethyl, isopropyl, which is optionally substituted by one to three X^1,

X^1 is independently selected from hydroxyl or phenyl

(2) -CO-Y,

Y is methyl, ethyl or isopropyl which is optionally substituted by one Y^1, or phenyl, pyridyl which is optionally substituted by one Y^2,

Y^1 is independently selected from dimethylamine or morpholinyl,

Y^2 is independently selected from amino sulfonyl,

(3) -$S(O)_m$-Z, m is 1 or 2,

Z is amino; and

R^3 is hydrogen.

4. A compound claimed in claim 3, or its pharmaceutically acceptable salts:

Wherein

R^1 is methyl;

R^2 is

(1) methyl, ethyl, or isopropyl, which is optionally substituted by one to two X^1,

X^1 is independently selected from phenyl,

(2) -CO-Y,

Y is methyl, ethyl or isopropyl, which is optionally substituted by one Y^1, or phenyl, pyridyl, which is optionally substituted by one Y^2,

Y^1 is independently selected from dimethylamine or morpholinyl,

Y^2 is independently selected from amino sulfonyl,

(3) -$S(O)_m$-Z, m is 1 or 2,

Z is amino; and

R^3 is hydrogen.

5. A compound claimed in claim 4, or its pharmaceutically acceptable salts and the said compound is selected from the followings:

(4*R*,5*S*,6*S*)-3-[(7*S*,8a*S*)-2-benzyloctahydropyrrolo[1,2-*a*]-pyrazin-7-ylthio]-6-[(*R*)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid,
(4*R*,5*S*,6*S*)-3-[(7*S*,8a*S*)-2-acetyloctahydropyrrolo[1,2-*a*]pyrazin-7-ylthio]-6-[(*R*)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid,
(4*R*,5*S*,6*S*)-6-[(*R*)-1-hydroxyethyl]-3-[(7*S*,8a*S*)-2-isobutyryl-octahydropyrrolo[1,2-*a*]pyrazin-7-ylthio]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid,
(4*R*,5*S*,6*S*)-3-[(7*S*,8a*S*)-2-benzoyloctahydropyrrolo[1,2-*a*]-pyrazin-7-ylthio]-6-[(*R*)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid,
(4*R*,5*S*,6*S*)-6-[(*R*)-1-hydroxyethyl]-4-methyl-7-oxo-3-[(7*S*,8a*S*)-2-picolinoyloctahydropyrrolo[1,2-*a*]pyrazin-7-ylthio]-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid,
(4*R*,5*S*,6*S*)-6-[(*R*)-1-hydroxyethyl]-4-methyl-7-oxo-3-[(7*S*,8a*S*)-2-(4-sulfamoylbenzoyl)octahydropyrrolo[1,2-*a*]pyrazin-7-ylthio]-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid,
(4*R*,5*S*,6*S*)-6-[(*R*)-1-hydroxyethyl]-4-methyl-7-oxo-3-[(7*S*,8a*S*)-2-sulfamoyloctahydropyrrolo[1,2-*a*]pyrazin-7-ylthio]-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid,
(4*R*,5*S*,6*S*)-6-[(*R*)-1-hydroxyethyl]-4-methyl-7-oxo-3-[(7*S*,8a*S*)-2-(4-sulfamoylbenzyl)octahydropyrrolo[1,2-*a*]pyrazin-7-ylthio]-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid,
(4*R*,5*S*,6*S*)-3-[(7*S*,8a*S*)-2-(2-guanidinoacetyl)octahydropyrrolo[1,2-*a*]pyrazin-7-ylthio]-6-[(*R*)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid,
(4*R*,5*S*,6*S*)-3-((7*S*,8a*S*)-2-(2-(dimethylamino)acetyl)octahydro-pyrrolo[1,2-*a*]pyrazin-7-ylthio)-6-((*R*)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid,
(4*R*,5*S*,6*S*)-3-((7*S*,8a*S*)-2-(2-(dimethylamino)propionyl)octa-hydropyrrolo[1,2-*a*]pyrazin-7-ylthio)-6-((*R*)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid,
(4*R*,5*S*,6*S*)-6-[(*R*)-1-hydroxyethyl]-4-methyl-3-[(7*S*,8a*S*)-2-(2-morpholinoacetyl)octahydropyrrolo[1,2-*a*]pyrazin-7-ylthio]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid,and
(4*R*,5*S*,6*S*)-6-[(*R*)-1-hydroxyethyl]-3-[(7*S*,8a*S*)-2-(2-hydroxy-ethyl)octahydropyrrolo[1,2-*a*]pyrazin-7-ylthio]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid.

6. A pharmaceutical dosage form comprising a compound claimed in claims 1-5, or its pharmaceutically acceptable salts, characterized in that the said dosage form contains one or more pharmaceutical carriers.

7. The use in the manufacture of a medicament for the treatment and/or prevention of infectious diseases comprising a compound claimed in claims 1-5, or its pharmaceutically acceptable salts.